Corcept Therapeutics (CORT) Reports Q4 EPS of $0.77
Tweet
Share
E-mailGet Alerts CORT Hot Sheet
Price: $110.29 -3.98%
Revenue Growth %: +56.0%
Financial Fact:
Net loss and comprehensive loss: 2.59M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Revenue Growth %: +56.0%
Financial Fact:
Net loss and comprehensive loss: 2.59M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Corcept Therapeutics (NASDAQ: CORT) reported Q4 EPS of $0.77, versus $0.04 reported last year. Revenue for the quarter came in at $53.3 million, versus $23.8 million reported last year.
GUIDANCE:
Corcept Therapeutics sees FY2018 revenue of $275-300 million.
For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
